Scatter factor/hepatocyte growth factor antagonist NK4 for the treatment of glioma
OwnerMichael Brandt, Marc Brockmann +3inventors
InventorsMichael Brandt, Marc Brockmann, Katrin Lamszus, Apollon Papadimitriou, Christine Schuell
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for the treatment of a tumor derived from glia cells of the central nervous system (CNS) of a patient, characterized in that the composition contains a pharmaceutically acceptable amount of a fragment of the hepatocyte growth factor, the fragment consisting of the N-terminal hairpin domain and the four kringle domains of the hepatocyte growth factor α-chain.
Claims10
A pharmaceutical composition for the treatment of a tumor derived from glia cells of the central nervous system (CNS) of a patient, the composition comprising a pharmaceutically acceptable amount of a N-terminal hairpin domain and four kringle domains of the hepatocyte growth factor α-chain (NK4).
A method for treating a patient having a tumor derived from glia cells in the central nervous system (CNS), comprising administering to the patient in need thereof a pharmaceutically acceptable amount of a N-terminal hairpin domain and four kringle domains of the hepatocyte growth factor α-chain (NK4).
A conjugate comprising a hepatocyte growth factor/scatter factor fragment NK4 protein covalently linked to a poly(ethylene glycol) group of the formula
- —CO—(CH2)x—(OCH2CH2)m-OR,
- with the —CO of the poly(ethylene glycol) group forming an amide bond with one of the amino groups of hepatocyte growth factor/scatter factor;
- wherein R is lower alkyl;
- X is 2 or 3;
- m is from about 450 to about 950 and is chosen so that the molecular weight of the conjugate minus the NK4 protein is from about 20 to about 40 kDa.
A pharmaceutical composition for the treatment of a tumor derived from glia cells of the central nervous system (CNS) of a patient, the composition comprising a pharmaceutically acceptable amount of a conjugate comprising a hepatocyte growth factor/scatter factor fragment NK4 protein covalently linked to a poly(ethylene glycol) group of the formula
- —CO—(CH2)x—(OCH2CH2)m-OR,
- with the —CO of the poly(ethylene glycol) group forming an amide bond with one of the amino groups of hepatocyte growth factor/scatter factor;
- wherein R is lower alkyl;
- X is 2 or 3;
- m is from about 450 to about 950 and is chosen so that the molecular weight of the conjugate minus the NK4 protein is from about 20 to about 40 kDa.
A method for treating a patient having a tumor derived from glia cells in the central nervous system (CNS), comprising administering to the patient in need thereof a pharmaceutically acceptable amount of a conjugate comprising a hepatocyte growth factor/scatter factor fragment NK4 protein covalently linked to a poly(ethylene glycol) group of the formula
- —CO—(CH2)x—(OCH2CH2)m-OR,
- with the —CO of the poly(ethylene glycol) group forming an amide bond with one of the amino groups of hepatocyte growth factor/scatter factor;
- wherein R is lower alkyl;
- X is 2 or 3;
- m is from about 450 to about 950 and is chosen so that the molecular weight of the conjugate minus the NK4 protein is from about 20 to about 40 kDa.
Dependencies are inferred from the claim text.